ReviewTranslational lung cancer research2025
A narrative review of immunotherapy for non-small cell lung cancer: current progress, sensitization approaches, and synergistic strategies.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: With increasing understanding of tumor immune tolerance mechanisms, a series of immune checkpoint molecules have been identified. Immune checkpoint blockade (ICB) therapy, which was developed based on these discoveries, has emerged as a promising strategy for the clinical treatment of non-small cell lung cancer (NSCLC), and has shown notable therapeutic benefits. However, the limited response rate remains a major barrier to further improving ICB efficacy and poses a significant challenge to the clinical management of NSCLC. This review summarizes recent advances in clinical immunotherapy for NSCLC and discusses future prospects in the field. Methods: A systematic literature search was performed using the official websites of organizations and databases, including PubMed, the United States (US) Food and Drug Administration (FDA), China's National Medical Products Administration (NMPA), the National Cancer Institute (NCI), the National Comprehensive Cancer Network (NCCN), the Chinese Society of Clinical Oncology (CSCO), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) The inclusion criteria were: (I) English-language articles published between 2004 and 2025; and (II) clinical studies specifically addressing immune checkpoint inhibitor (ICI) therapy in NSCLC populations. Key Content and Findings: Researchers have explored various approaches from drug development and treatment response evaluation to combination strategies, and have made substantial progress in enhancing the effectiveness of ICB therapy. Conclusions: ICB therapy for NSCLC has evolved from monotherapy to multimodal combination approaches, and significant breakthroughs have been achieved; however, three major challenges persist; that is, acquired drug resistance, a lack of reliable biomarkers, and the suboptimal management of special patient populations. To address these issues, future research should focus on: (I) elucidating resistance mechanisms through multi-omics approaches; (II) developing novel biomarkers and next-generation targeted agents; and (III) refining combination therapy regimens. These coordinated efforts will ultimately enable personalized precision immunotherapy tailored to individual patients' molecular profiles and clinical characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.